Alzheimer's Psychosis Studies Should Measure Improved Functional Status

Studies of drugs for psychosis related to Alzheimer's disease should measure improvement in patients' functional status as well as amelioration of symptoms of psychosis, FDA's Psychopharmacologic Drugs Advisory Committee agreed at its March 9 meeting.